The answer to that question may well depend on "why" it had a negligible effect - if indeed it did. Much has been made of the similarities between the HCV and HBV treatments. If, for example, the vector was a problem, then it would make sense for the TT-034 results to be delayed in order to buy time to develop a new vector. Then, when the TT-034 data is released, the company will be able to point to a change in the design of the HBV treatment which eliminates the problem.
If big pharma is actually sniffing around, I am sure that they would want to be assured that any shortcomings of TT-034 will be overcome for HBV before signing any deal.
TT-034 data collection finishes this month, so we don't have long to wait.
- Forums
- ASX - By Stock
- BLT
- Panno speaks on recent changes
Panno speaks on recent changes, page-4
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online